Rallybio (NASDAQ:RLYB) Releases Quarterly Earnings Results

Rallybio (NASDAQ:RLYB) announced its quarterly earnings results on Wednesday. The company reported ($1.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.26), FiscalAI reports. The business had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.23 million. Rallybio had a negative return on equity of 56.93% and a negative net margin of 1,046.39%.

Rallybio Stock Performance

NASDAQ RLYB traded down $0.10 during trading hours on Thursday, hitting $14.25. 10,838 shares of the company traded hands, compared to its average volume of 235,527. The business’s 50-day moving average is $9.70 and its 200-day moving average is $6.93. Rallybio has a twelve month low of $2.16 and a twelve month high of $15.31. The stock has a market capitalization of $75.38 million, a price-to-earnings ratio of -5.57 and a beta of -1.10.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on RLYB shares. Wall Street Zen upgraded Rallybio to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rallybio in a report on Friday, May 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Insider Buying and Selling

In related news, major shareholder Adar1 Capital Management, Llc purchased 120,804 shares of Rallybio stock in a transaction that occurred on Monday, May 4th. The stock was purchased at an average cost of $13.97 per share, with a total value of $1,687,631.88. Following the completion of the transaction, the insider owned 744,683 shares of the company’s stock, valued at approximately $10,403,221.51. This trade represents a 19.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders purchased 206,705 shares of company stock worth $2,890,110 over the last ninety days. Corporate insiders own 10.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. XTX Topco Ltd boosted its position in Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after purchasing an additional 38,205 shares during the last quarter. Renaissance Technologies LLC boosted its position in Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after purchasing an additional 120,892 shares during the last quarter. Geode Capital Management LLC boosted its position in Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after purchasing an additional 2,996 shares during the last quarter. Susquehanna International Group LLP lifted its position in shares of Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after buying an additional 113,031 shares during the last quarter. Finally, Citadel Advisors LLC lifted its position in shares of Rallybio by 576.1% in the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after buying an additional 373,821 shares during the last quarter. 90.34% of the stock is owned by institutional investors and hedge funds.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.